Viekira Pak contains three new drugs — ombitasvir, paritaprevir and dasabuvir — that work together to inhibit the growth of HCV. It also contains ritonavir, a previously approved drug. The efficacy of the drug was evaluated in six clinical trials enrolling 2,308 participants. However, the most common side effects reported by clinical trial participants were feeling tired, itching, feeling weak or lack of energy, nausea and having trouble sleeping.
Viekira Pak is marketed by AbbVie.
More articles on gastroenterology:
gMed completes initial adoption of ASGE/ACG colonoscopy quality metrics
Covidien’s capsule endoscopy featured in Cooper Hewitt exhibit in New York
Is anesthesia dosage adjusted appropriately for different ages? Study says no
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
